Credit: Scott Bodell/MedicalImages.com The authors outline preventative pharmacologic therapies for COPD exacerbations and a patient-tailored approach to management. Chronic obstructive pulmonary ...
In patients with chronic obstructive pulmonary disease (COPD), increasing frequency and severity of exacerbations were linked to a higher risk of future exacerbations and all-cause and COPD-related ...
Patients with chronic obstructive pulmonary disease (COPD) face a significant cardiovascular burden both before and after diagnosis. Analyses presented at the European Respiratory Society (ERS) ...
New research shows that individual exacerbations in chronic obstructive lung disease (COPD) themselves increase the likelihood of repeat exacerbations, even after five days of full, asymptomatic ...
Woman suffering an anxiety attack alone in the night How does a delay in initiating triple therapy affect patients with COPD with a history of several moderate COPD exacerbations during a 1-year ...
Telemedicine significantly improved quality of life and inhaler technique in advanced COPD patients compared to traditional ...
bronchodilators, COPD Triple therapy with budesonide/glycopyrrolate/formoterol fumarate in patients with COPD, regardless of exacerbation history, reduced ...
The biologic dosed every 2 weeks reduced moderate or severe COPD exacerbations over 52 weeks by a relative 15.4% compared ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. COPD exacerbations went down by 51% in patients with ...
Poor quality of sleep was found to have a strong association with symptomatic exacerbations of chronic obstructive pulmonary disease, according to a recent Canadian study presented at the 2016 ...
Please provide your email address to receive an email when new articles are posted on . Minimum pitch in the morning was significantly higher at exacerbation onset and peak vs. baseline. In the ...
Paris and Tarrytown, N.Y. November 27, 2023. The second Dupixent® (dupilumab) investigational Phase 3 chronic obstructive pulmonary disease (COPD) trial (NOTUS) has shown that Dupixent significantly ...